The Inflammatory Price of Clearing Amyloid: A New Framework for ARIA Surveillance
A new editorial framework addresses the critical challenge of amyloid-related imaging abnormalities (ARIA), a spectrum of MRI-detectable complications linked to anti-amyloid monoclonal antibody immunotherapies for Alzheimer’s disease. The pathophysiology involves the interplay between amyloid-β clearance and vascular inflammation, where antibodies destabilize cerebrovascular integrity, particularly in patients with pre-existing cerebral amyloid angiopathy. This process mobilizes Aβ fragments, overwhelms perivascular drainage, and triggers an inflammatory cascade and blood-brain barrier disruption, leading to vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H). The apolipoprotein E (APOE) ε4 allele, especially homozygosity, remains the strongest genetic risk factor due to its association with vascular amyloid burden and BBB impairment. The article calls for robust global surveillance strategies to manage these immunotherapy side effects.
Study Significance: For immunologists and clinicians developing or administering biologic therapies, this work underscores the complex immunopathology that can arise when powerful monoclonal antibodies engage their targets in vivo. It highlights the necessity of understanding cytokine cascades and innate immune responses, like vascular inflammation, as central mediators of treatment-related adverse events. This framework directly informs risk stratification, monitoring protocols, and the future design of safer immunotherapies that aim to modulate adaptive immunity without triggering damaging innate inflammatory pathways.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
